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Considerable geographic variation exists in the relative use
of hemodialysis (HD) vs peritoneal dialysis (PD). Studies
comparing survival between these modalities have yielded
conflicting results. Our aim was to compare the survival of
Dutch HD and PD patients. We developed Cox regression
models using 16 643 patients from the Dutch End-Stage
Renal Disease Registry (RENINE) adjusting for age, gender,
primary renal disease, center of dialysis, year of start of
renal replacement therapy, and included several interaction
terms. We assumed definite treatment assignment at day 91
and performed an intention-to-treat analysis, censoring
for transplantation. To account for time dependency, we
stratified the analysis into three time periods, 43–6, 46–15,
and 415 months. For the first period, the mortality hazard
ratio (HR) of PD compared with HD patients was 0.26 (95%
confidence interval (CI) 0.17–0.41) for 40-year-old non-
diabetics, which increased with age and presence of diabetes
to 0.95 (95% CI 0.64–1.39) for 70-year-old patients with
diabetes as primary renal disease. The HRs of the second
period were generally higher. After 15 months, the HR was
0.86 (95% CI 0.74–1.00) for 40-year-old non-diabetics and 1.42
(95% CI 1.23–1.65) for 70-year-old patients with diabetes
as primary renal disease. We conclude that the survival
advantage for Dutch PD compared with HD patients
decreases over time, with age and in the presence of diabetes
as primary disease.
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The relative use of hemodialysis (HD) vs peritoneal dialysis
(PD) for treatment of end-stage renal disease varies consider-
ably across countries. In 2002, 0.5% of dialysis patients in
Luxembourg underwent PD, whereas 48.4% used this
modality in New Zealand.1 Practice varies not only among
but also within countries, as has been reported for the United
States.2 Although cultural factors and patient or physician
preference may play a role, as well as reimbursement policy
decisions, survival associated with both therapy modalities is
an important consideration in the treatment decision.
Studies comparing patient survival on HD and PD,
however, have yielded conflicting results. Possible explana-
tions for these inconsistent results include underlying
differences in the populations studied (e.g., incident vs
prevalent patients, elderly vs general population), differences
in methodology used (e.g., intention-to-treat vs as-treated),
as well as unavailability of information on important
confounders in several studies (e.g., presence and/or severity
of co-morbid conditions). Although differences in measured
clinical or demographic characteristics can be adjusted in
multivariable regression analyses, confounding by unmea-
sured characteristics remains a threat to validity. It has been
suggested that using information on the treatment center can
be used to further reduce bias.3,4 This can be conducted in
several ways, such as through multivariable modeling,
multilevel modeling, or including center information in
exposure propensity scores.5,6 Furthermore, the relative
mortality risk of HD compared with PD patients may differ
for various patient groups. In addition, the relative risks may
change over time after the initiation of dialysis.7–10
In The Netherlands, a relatively high proportion of patients
initiate renal replacement therapy (RRT) using PD. We
conducted this study to compare mortality of incident HD
and PD patients in the Netherlands, using Dutch registry data.
RESULTS
The RENINE Registry prospectively collected data of 20 687
patients who started RRT between 1 January 1987 and
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31 December 2002. We discarded 2157 patients who died
during the first 90 days of RRT. Of the remaining patients, we
excluded 517 patients because they were younger than 18
years and another 19 patients who had more than one
episode of recovery of renal function or death directly
following a period of renal recovery. Of the remaining
patients, there were 699 who had received a pre-emptive
transplantation before or at day 91. We excluded 625 patients
from centers treating fewer than 20 dialysis patients or fewer
than five PD patients and another 27 patients for whom
center information was not available. As a result, our final
sample included 16 643 patients from 47 centers. Mean age
was 59 years (s.d.: 15.3) and 58.8% were male. Descriptive
characteristics of patients are shown in Table 1. The
Kaplan–Meier survival plot (Figure 1) showed a higher crude
survival for PD compared with HD patients (log-rank test:
Po0.001).
Multivariable regression analysis
In the univariable Cox model, dialysis modality was
associated with survival: patients who initiated RRT using
PD had a 30% lower mortality compared with HD patients
(hazard ratio (HR)¼ 0.70; 95% confidence interval (CI):
0.67–0.74; Po0.001). The coefficients of all other univariable
models were also statistically significant, both in the overall
population and in the HD and PD groups (see Table 2). The
coefficient for the year of starting RRT was not significant
in the total population, because its effect was in opposite
directions for HD and PD patients. With increasing year
of start of RRT, the relative risk of dying increased for
HD patients and decreased for PD patients. Center was a
significant univariable predictor of modality (Po0.001, data
not shown).
The multivariable Cox model, adjusted for age, gender,
primary renal disease, year of first RRT, and treatment center
but without interaction terms revealed that mortality of PD
patients and HD patients did not differ (HR¼ 0.99; 95% CI:
0.94–1.05). Of the interaction variables tested in this multi-
variable model, however, four were statistically significant:
age by modality (HD or PD) and diabetes as the primary
cause of renal disease (PRD-DM) by modality, by age, and by
gender (Table 3). An analysis using propensity scores was also
undertaken and the results were virtually unchanged.
Additional analyses using center size as a covariate yielded
essentially identical results (not shown).
Several interactions with time were statistically significant
in the multivariable Cox model indicating violations of the
proportionality assumption. We tested various time-stratifi-
cation strategies. Finally, we stratified time into three periods:
43–6, 46–15, and beyond 15 months. For each of these
periods, the relative mortality risk of PD compared with HD
patients appeared constant over time. In order to illustrate
the change in relative hazards over time and to account for
the variables that were effect modifiers of the treatment
variable (age, PRD-DM), we calculated HRs of PD compared
with HD patients for representative values of these variables.
Table 1 | Baseline characteristics of study cohort
All patients HD PD P-value
Number (%) 16 643 10 841 (65.1) 5802 (34.9)
Age (s.d.) (years) 59.0 (15.3) 61.8 (14.6) 53.6 (15.0) o0.001
Female gender (%) 41.2 42.5 38.7 o0.001
Primary renal disease (%) o0.001
GN 13.7 11.1 18.5
HT 11.4 11.7 10.8
RVD 8.7 9.8 6.6
DM 15.2 14.9 16.0
Other 51.0 52.5 48.1
Year of first RRT (%) o0.001
1987–1990 17.0 18.0 14.9
1991–1994 23.5 23.2 24.0
1995–1998 28.6 28.3 29.0
1999–2002 31.0 30.5 32.0
Years of follow-up (s.d.) 2.38 (2.14) 2.42 (2.24) 2.32 (1.95) 0.007
DM, diabetes mellitus; GN, glomerulonephritis; HD, hemodialysis; HT, hypertension;
PD, peritoneal dialysis; RRT, renal replacement therapy; RVD, renovascular disease.
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Figure 1 | Unadjusted survival of dialysis patients. Kaplan–Meier
curves of survival of HD (black line) and PD (grey line) patients,
censored for transplantation (log-rank test: Po0.001). *Follow-up
censored for transplantation in years.
Table 2 | Univariable associations with mortality
HD PD All patients
HR P-value HR P-value HR P-value
Age (per year) 1.04 o0.001 1.06 o0.001 1.05 o0.001
Female vs male gender 0.94 0.02 0.80 o0.001 0.91 o0.001
Primary renal disease versus GNa
HT 1.47 o0.001 2.15 o0.001 1.72 o0.001
RVD 2.35 o0.001 3.80 o0.001 2.86 o0.001
DM 2.11 o0.001 3.49 o0.001 2.55 o0.001
Other 1.38 o0.001 1.61 o0.001 1.53 o0.001
Year of first RRT (per year) 1.02 o0.001 0.99 o0.001 1.00 0.18
PD vs HD — — — — 0.70 o0.001
DM, diabetes mellitus; GN, glomerulonephritis; HD, hemodialysis; HR, hazard ratio;
HT, hypertension; PD, peritoneal dialysis; RRT, renal replacement therapy; RVD,
renovascular disease.
aCompared with GN as reference group.
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We used four ages, 40, 50, 60, and 70 years, for detailed
presentation (Table 4). For the eight groups defined by these
values of age and the presence vs absence of PRD-DM, the
relative mortality risk of PD patients compared with HD
patients increased over time, that is, the relative survival
benefit diminished (Table 4). And for all time-strata, this
relative PD survival benefit decreased with increased age and
with the presence of PRD-DM. Among non-PRD-DM
patients, the relative survival advantage associated with PD
was highest for 40-year olds, although this relative advantage
decreased over time, from an HR of 0.26 (95% CI: 0.17–0.41)
in the time period of 43–6 months to an HR of 0.86 (95%
CI: 0.74–1.00) in the period after 15 months. For 40- and 50-
year-old patients with PRD-DM and for 50-, 60-, and 70-
year-old patients without PRD-DM, the early relative survival
advantage associated with PD disappeared over time. PD was
even associated with worse relative survival after 15 months
for 50-year-old PRD-DM patients (HR 1.17, 95% CI:
1.00–1.35) and 70-year-old patients without PRD-DM (HR
1.16, 95% CI: 1.07–1.25). Similarly, for 60- and 70-year-old
patients with PRD-DM, PD was associated with a signifi-
cantly worse relative survival (HR respectively 1.29, 95% CI
1.12–1.48 and 1.42, 95% CI 1.23–1.65) after 15 months,
although there was no significant relative survival advantage
for either modality up to 15 months.
To assess the impact of these HRs on actual cumulative
survival, we constructed survival curves for these eight
groups (Figure 2a–h). As can be deduced from these curves,
the differences in absolute survival were similar as those with
respect to the relative survival or HRs, with one exception.
For 50-year-old patients without PRD-DM, we concluded
from the HRs that the relative survival advantage disappeared
over time, however, the cumulative survival benefit of PD
remained over the entire observation period (Figure 2c).
DISCUSSION
In this comprehensive study of all patients who initiated
chronic dialysis treatment between 1987 and 2002 in The
Netherlands, unadjusted mortality of PD patients was 30%
lower compared with HD patients. Multivariable adjustment
for age, gender, primary renal disease, year of first RRT, and
dialysis center, however, showed that the HR was not
constant over time, but increased in favor of HD, with
higher age, and in those whose primary renal disease was
DM. In younger patients, PD was associated with superior
survival in the first 15 months of RRT, independent of
whether DM was the original renal disease. Among older
patients, this association was only present for the first few
months and only in those patients whose underlying renal
disease was not DM. Independent of underlying renal disease,
PD was associated with higher mortality after 15 months in
patients older than 70 years of age. Examining the cumulative
survival curves enables us to scrutinize the other aspect of
this study, overall survival (Figure 2). For non-PRD-DM
patients, PD was associated with a comparable (age 60 and
70) or better (age 40 and 50) overall survival compared with
HD. Among PRD-DM patients, PD and HD showed
equivalent survival among younger patients (age 40 and
50), but HD was associated with greater survival among older
patients (age 60 and 70).
Our findings corroborate the existing literature on the
decrease in relative survival of PD patients as compared with
HD patients over time. Termorshuizen et al.10 reported that
mortality during the first two years was not different between
HD and PD patients among participants of the NECOSAD
study. However, they observed a higher relative mortality of
PD patients after two years of treatment. Jaar et al.11 came to
similar conclusions in their recent study of 1041 incident
dialysis patients in the US. Fenton et al.7 concluded that
Canadian PD patients had a significantly higher survival than
HD patients, the effect being largest for the first two years on
dialysis. Heaf et al.9 reported a survival advantage for Danish
PD patients for the first 1–2 years, but after 2.5 years this
association was reversed in patients with diabetes.8 Although
these studies allow for different conclusions regarding the
Table 3 | Multivariable adjusted model
HR P-value
Age (per year) 1.05 o0.001
Female vs male gender 0.87 o0.001
Primary renal disease vs GNa o0.001
HT 1.22 o0.001
RVD 1.68 o0.001
DM 5.65 o0.001
Other 1.31 o0.001
Year of first RRT (per year) 0.99 0.005
Dialysis center o0.001
Peritoneal vs hemodialysis 0.43 o0.001
Age dialysis modality 1.01 o0.001
DMdialysis modality 1.22 0.002
AgeDM 0.98 o0.001
GenderDM 1.20 0.002
DM, diabetes mellitus; GN, glomerulonephritis; HR, hazard ratio; HT, hypertension;
RRT, renal replacement therapy; RVD, renovascular disease.
aCompared with GN as reference group.
Table 4 | Associations between dialysis modality and
mortality
HRs of PD vs HD (95% CIs)a
Age DM 43–6 months 46–15 months 415 months
40 No 0.26 (0.17; 0.41) 0.51 (0.39; 0.68) 0.86 (0.74; 1.00)
40 Yes 0.40 (0.23; 0.68) 0.59 (0.44; 0.81) 1.06 (0.88; 1.26)
50 No 0.35 (0.25; 0.48) 0.62 (0.51; 0.76) 0.95 (0.85; 1.05)
50 Yes 0.53 (0.34; 0.83) 0.72 (0.56; 0.93) 1.17 (1.00; 1.35)
60 No 0.46 (0.37; 0.58) 0.75 (0.65; 0.87) 1.05 (0.97; 1.13)
60 Yes 0.71 (0.48; 1.04) 0.87 (0.71; 1.09) 1.29 (1.12; 1.48)
70 No 0.62 (0.50; 0.76) 0.92 (0.80; 1.05) 1.16 (1.07; 1.25)
70 Yes 0.95 (0.64; 1.39) 1.07 (0.85; 1.33) 1.42 (1.23; 1.65)
CI, confidence interval; DM, diabetes as primary renal disease; HD, hemodialysis; HR,
hazard ratio; PD, peritoneal dialysis.
aFrom models including age, gender, primary renal disease, year of start of RRT,
center and the interaction terms age by modality, diabetes by modality, age by
diabetes, and gender by diabetes.
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presence of an initial survival advantage for PD patients, the
time trends in survival differences are similar; the relative
mortality risk of PD patients has consistently been reported
to increase over time. Differences regarding the initial
survival advantage of PD during the first years of dialysis
in these studies might be explained by different analytical
approaches, prognostic factors available for study, and
regional differences in patient population and dialysis
practice.
The initial survival advantage of PD patients in our
study might be explained by HD patients having higher
co-morbidity at initiation of dialysis therapy.12 If HD patients
with the highest burden of co-morbidity die early resulting in
healthier HD patients surviving, mortality rates of HD
patients would then decrease over time. PD patients, who are
generally healthier than HD patients initially, would develop
higher mortality over time as they accumulate other co-
morbidities. Some of these aforementioned studies did
correct for co-morbidity, however, and still observed time
trends similar to our study.7–10 Alternatively, the higher dose
of delivered dialysis for PD patients initially might account
for the time trend in relative mortality. Collins et al.8
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Figure 2 | Adjusted survival curves of HD and PD patients. (a–h) Curves of survival of HD (black line) and PD (grey line) patients, censored for
transplantation, for various ages (years) and stratified by presence of diabetes mellitus (DM) being the primary renal disease. *Follow-up
censored for transplantation in years.
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reported, though, that initial delivered dose was not as
different for HD and PD patients as had generally been
believed. Finally, it has also been suggested that the short-
term survival advantage of PD patients might be explained by
better preservation of residual renal function in patients
treated with PD as compared with patients treated with
HD.13 Residual kidney function has been shown to be an
independent predictor of mortality for both HD14 and PD15
patients. As time progresses, residual kidney function
declines and PD alone might not suffice to maintain adequate
clearance. Therefore, some have advocated an Integrative
Care Approach, starting RRT with PD and later switching
to HD as residual renal function deteriorates.9,16 To inform
such an approach, it is important to consider both data on
period-specific HRs and on cumulative survival over time.
Even if one modality may be associated with greater mortality
during later stages of RRT, the strategy may still be superior
because of lower mortality during earlier time-periods, and
vice versa.
In our study, we also found that the HR of PD compared
with HD patients increased with age and in the presence of
diabetes as primary renal disease. This effect modification
had also previously been reported,12,17–19 although contrast-
ing findings were also described by Keshaviah et al.20 The
latter group described a similar two-year survival for HD and
PD patients, independent of age and diabetic status, when
adjusting for co-morbidity, serum albumin, and dialysis dose.
This controversy might be explained by differences in the
covariate adjustment: Keshaviah included dialysis dose as a
covariate, whereas the other studies did not. Jaar et al.11 did
find age to be an effect modifier, whereas diabetes was not. In
their study, initial dialysis dose as well as cardiovascular
morbidity was among the included covariates. However, with
a cohort of just over 1000 patients, their statistical power was
rather limited to detect any effect modification on prognostic
main effects. Our study confirms the findings of Vonesh et al.
who analyzed 398 940 incident US dialysis patients from the
United States Renal Data System. These authors also reported
effect modification by age and diabetes and found a similar
time trend in relative survival of HD compared with PD
patients in age- and diabetes-stratified subgroups.19
Some limitations of our study deserve mention. The
RENINE database does not include data on co-morbidity,
but information on primary renal diagnosis is available. The
most important co-morbid condition, diabetes, is likely well
represented in the subgroup identified with diabetes as
underlying renal disease, as diabetes and PRD-DM are likely
to correlate strongly. Other factors that have been reported to
affect dialysis mortality were also not available for study:
ethnicity,8,21 nutritional markers,21–23 delivered therapy,20
and transplant eligibility.9
Important factors, other than survival, in selecting dialysis
modality for an individual patient would include HD and
PD-associated quality-of-life and a patient’s living arrange-
ments and personal preference. Also the nephrologist’s
preference and the reimbursement system in a specific
country are known to influence dialysis modality selec-
tion.24,25 These aspects are beyond the scope of our study.
From our findings, we conclude that there is an initial
survival advantage for PD patients compared with HD
patients in The Netherlands. Over time, with advancing age,
and in the presence of diabetes as primary disease, this relative
survival advantage vanishes, and even reverses with time.
MATERIALS AND METHODS
Patients
We included all incident patients who started RRT between 1
January 1987 (start of prospective registration) and 31 December
2002 from the Dutch End Stage Renal Disease Registry (RENINE).
We excluded patients younger than 18 years, patients who under-
went RRT for less than 30 days, patients who had more than one
episode of recovery of renal function, or who died directly following
a period of renal recovery, patients who received a pre-emptive
transplantation, patients who died during the first 90 days of RRT
and patients from centers treating fewer than 20 dialysis patients or
fewer than five PD patients. The outcome of interest was all-cause
mortality, as registered by RENINE. The registry collects informa-
tion on date and cause of death and verifies its information yearly
with all centers.26,27 From registry data, we also determined age and
gender of patients. In the database, primary renal diagnosis was
coded according to the classification of the European Renal
Association-European Dialysis and Transplantation Association
(ERA-EDTA). We aggregated these into five categories: glomerulo-
nephritis (PRD-GN), hypertension (PRD-HT), renovascular disease
(PRD-RVD), diabetes mellitus (PRD-DM), and a category for all
other renal diagnoses (PRD-OTH). Furthermore, we used registry
data on dialysis modality, year of start of dialysis, and the center at
which dialysis was started.
Analysis
We adopted an intention-to-treat perspective and considered the
dialysis modality on day 91 to be the definite modality. We left-
censored survival time for the first 90 days and right-censored at
first transplantation or 31 December 2002, whichever occurred first.
We compared Kaplan–Meier survival curves of HD and PD patients,
using the log-rank test.
To estimate the independent comparison between PD and HD
mortality by controlling for observed potential confounders, we
used a multivariable regression adjustment approach. The first step
was to estimate univariable Cox proportional hazards models for all
available variables. Age and year of start of dialysis were entered into
the model as continuous variables and all other variables as
categorical variables. All statistically significant variables (Po0.05)
from the univariable analyses were put into a multivariable Cox
proportional hazards model. From the full multivariable model, we
explored the significance of a quadratic term (age) and several two-
way and three-way interaction terms. We tested for center effects by
entering center as a categorical variable into the multivariable model.
In the final Cox model, we tested for violations of the propor-
tional hazards assumption by testing for significance of time-
dependent variables. As the proportionality assumption was violated
for the main exposure variable, we applied time stratification, thus
ensuring absence of time dependency within time strata. For all these
analyses, we calculated HRs and 95% CI for PD relative to HD
mortality within each time interval. In addition, we presented
cumulative survival curves stratified by PD vs HD. An HR reflects a
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relative survival difference for a period to which the HR pertains.
Because the proportional hazards assumption was not satisfied, we
calculated different HRs for different time periods. The long-term
survival and life expectancy over the entire observation period are
determined by the magnitude of the HRs and the duration of the
period to which these ratios apply, in other words, by the cumulative
effect of the different HRs. Absolute survival differences are therefore
best reflected in differences in (the area under) the cumulative
survival curves.
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